# Phenylbutyrate in Proteinuric Nephropathies

> **NCT02343094** · PHASE2,PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 26 (actual)

## Conditions studied

- Proteinuric Diseases

## Interventions

- **DRUG:** PBA 7,5g/d
- **DRUG:** PBA 15g/d

## Key facts

- **NCT ID:** NCT02343094
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02343094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02343094, "Phenylbutyrate in Proteinuric Nephropathies". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02343094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*